Please login to the form below

Not currently logged in
Email:
Password:

Wilson Therapeutics

This page shows the latest Wilson Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Alexion eyes Soliris combo with $930m deal to buy Achillion

Alexion eyes Soliris combo with $930m deal to buy Achillion

Other bolt-on deals to boost its product portfolio and pipeline include the $1.2bn takeover of  Syntimmune and $855m purchase of  Wilson Therapeutics last year.

Latest news

  • Pfizer goes big on gene therapy with $500m facility spend Pfizer goes big on gene therapy with $500m facility spend

    That was followed swiftly by a partnership with Spark Therapeutics that brought in a clinical-stage  haemophilia B therapy now in phase 3 testing, and another deal with Sangamo for a  ... It also took a 15% stake in  Vivet Therapeutics and its lead

  • Alexion targets RNAi with $637m Dicerna deal Alexion targets RNAi with $637m Dicerna deal

    The new deal adds to others made by Alexion this year, including the $855m acquisition of rare disease company Wilson Therapeutics in April and privately-held autoimmune disease specialists Syntimmune in

  • Alexion adds to pipeline with $1.2bn Syntimmune buy Alexion adds to pipeline with $1.2bn Syntimmune buy

    In the meantime, however, it’s also been adding to its earlier-stage pipeline and the Syntimmune acquisition comes a few months after it snapped up Swedish biotech Wilson Therapeutics for ... $855m, adding orally-active copper binder WTX-101 in phase

  • Abingworth raises $315m to expand hunt for promising biotechs Abingworth raises $315m to expand hunt for promising biotechs

    The acquisitions of rare disease specialist Wilson Therapeutics by Alexion for $855m and of IFM Therapeutics – an immuno-oncology player – by Bristol-Myers Squibb for $1.3bn are recent successes for ... Abingworth has shown it is prepared to back

  • Alexion adds to pipeline rebuild with $855m Wilson buy Alexion adds to pipeline rebuild with $855m Wilson buy

    $855m offer for rare disease company Wilson Therapeutics. ... Ludwig Hantson, Alexion’s chief executive, said: “The acquisition of Wilson Therapeutics is a strong strategic fit for Alexion given the overlap with our current clinical and commercial

More from news
Approximately 2 fully matching, plus 5 partially matching documents found.

Latest appointments

  • IGEM Therapeutics appoints Dr Tim Wilson as CEO IGEM Therapeutics appoints Dr Tim Wilson as CEO

    Wilson has over 28 years’ experience in the life sciences sector, ranging from venture capital and start-ups to investment banking and equity research. ... Wilson has worked for numerous private and public life science companies in the US and Europe at

  • Therachon strengthens management team Therachon strengthens management team

    He currently serves as chairman of Asceneuron, Complix and InteRNA, and as a non-executive director at Hansa Medical, Sobi, Wilson Therapeutics and Dutch Top Sector Life Sciences and Health.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

White Paper for download - Explaining the price of your product
In this white paper, he breaks down the pricing options available to you, shares stories from his extensive experiences, and talks you through how to better define your pricing, step-by-step....
OPEN Health expands offering with the launch of a new Learning & Development specialist team
Enhanced expertise to deliver impactful internal training programmes for healthcare clients...
Figure 1 Clarivate
The changing nature of approvals – what does the future hold?
The 2019 CMR International Pharmaceutical R&D Factbook...

Infographics